SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending as investors await the results of a key merger vote, anticipating the company's strategic shift towards becoming a major Bitcoin treasury company. Community members are actively discussing potential short squeezes and comparing it to other high-flying stocks in the sector, fueled by the prospect of significant financial backing and a shift in business strategy. Chatter suggests a possible surge upon news releases, with speculation around institutional interest and strategic positioning ahead of the anticipated announcement.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's stock is trending downwards as the market reacts negatively to the company's latest product announcements, particularly the new iPhone. The community expresses concerns around lack of innovation and whether the new features justify an upgrade, contributing to a sell-off. Many traders believe the stock predictably declines following these events.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

Fueled by news of a strategic expansion into cryptocurrency and blockchain AI solutions, QMMM is experiencing significant volatility and a price surge, attracting both bulls and bears. The community is actively discussing the stock's potential as a crypto play and comparing it to other recent high-flying tickers. Some traders are wary of the Hong Kong-based company, while others are targeting further gains.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following news of a significant AI infrastructure deal with Microsoft, sparking considerable enthusiasm among investors. Community discussions revolve around the potential for further growth and partnerships, with some speculating on new price targets. Despite some profit-taking, the overall sentiment appears bullish due to the deal's potential impact on the company's revenue and market position in the high-performance computing sector.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as the stock experiences a significant surge, driven by reaffirmed FY25 EPS guidance and positive Medicare Advantage ratings news. The community is actively discussing the potential for further gains, with some eyeing a return to previous highs, while others debate optimal profit-taking strategies amidst the bullish momentum. Some investors believe the move is Warren Buffett-related and/or a possible leak of positive news regarding the DOJ investigation.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CaliberCos ($CWD) is trending as traders discuss its volatile price action, drawing comparisons to recent surges in other stocks like $QMMM and $OCTO. The community is highlighting the stock's low float and potential for a short squeeze, while others are wary of a potential pump and dump, with some reporting significant losses. The discussion is also fueled by the company's recent announcement regarding its digital asset treasury strategy, involving the purchase of Chainlink tokens.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending downwards as the community discusses concerns over increased competition from AI-powered language tools, including Apple's new live translation feature for AirPods and Google's language learning updates to Google Translate. Some investors worry that these technologies could make Duolingo's services obsolete, while others remain optimistic about Duolingo's long-term prospects due to its gamified learning approach and established brand.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Wave Life Sciences (WVE) tumbled over 19% on Wednesday after the company announced that its WVE-006 led to RNA editing in all participants treated in a trial evaluating the therapy as a treatment for alpha-1-antitrypsin deficiency (AATD).AATD is an inherited genetic disorder that reduces the production of the AAT protein, which is crucial for protecting the lungs and liver. It is caused by a genetic mutation, and WVE-006 is designed to address the manifestations of AATD by correcting the mutation.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-ongoing">announced</a> on Wednesday that WVE-006 resulted in RNA editing in all treated participants, with durable production of serum AAT at levels associated with a lower risk of liver and lung disease following repeat 200 mg doses.Despite the impressive first demonstration of a dynamic acute phase response post-RNA editing in alpha-1-antitrypsin deficiency, Wave Life's stock performance suggests the Street expected a greater increase in AAT protein, Leerink said. Leerink raised its price target on Wave Life Sciences to $26 from $24 and kept an ‘Outperform’ rating on the shares.Leerink further thinks investors should take advantage of this weakness to buy the stock ahead of additional important catalysts, which it remains optimistic investors will appreciate despite today's confusion.H.C. Wainwright analyst Andrew Fein, meanwhile, said Wave’s stock decline despite the “encouraging” data was an “overreaction.” The analyst stated that these results strengthen the firm's conviction that WVE-006 can deliver both lung and liver benefits, and the firm believes the current data, excluding the 400 mg multiple ascending dose data, "still shows an approval endpoint.” The analyst has a ‘Buy’ rating and $22 price target on Wave Life Sciences shares.Data from both the 200 mg and 400 mg single-dose cohorts support a monthly or less frequent subcutaneous dosing regimen, Wave Life Sciences said. Dosing is ongoing in the 400 mg multidose cohort with a monthly dosing regimen, for which Wave expects to deliver data in the first quarter of 2026. Further, all adverse events observed in the study were mild to moderate in intensity, and there were no serious adverse events or discontinuations, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WVE">WVE</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_2_24_05_PM_png_6c95483e4e.webp" alt="WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="623" height="59"><figcaption>WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>GSK has the exclusive global license for WVE-006. Development and commercialization responsibilities will transfer to GSK after Wave completes the study. Wave is eligible for up to $525 million in milestone payments, as well as tiered royalties on net sales, for WVE-006.WVE stock is down 37% this year but up approximately 40% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-reports-near-four-percent-jump-in-us-vehicle-sales-in-august/chwT6RHRd8r">Ford Reports Near 4% Jump In US Vehicle Sales In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why

Wave Life Sciences said Wednesday that its therapy WVE-006 successfully edited RNA in all trial participants, producing lasting levels of a key protein tied to lower risks of liver and lung disease after repeat 200 mg doses.

Equity

BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Top Analyst Reports for NVIDIA, Chevron & Booking

NVIDIA rides AI and GPU demand, Chevron leverages Hess and Permian output, while Booking gains from strong travel momentum.

GSK Adds Around $5B in a Month: Here's How to Play the Stock

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

GSK has secured UK approval for Blujepa (gepotidacin), the first new type of oral antibiotic for urinary tract infections (UTIs) to be cleared in nearly three decades as the drugmaker seeks to grow its infectious disease portfolio.The Medicines and Healthcare products Regulatory Agency (MHRA),&nbsp;the UK’s medicines regulator, has approved Blujepa for use in women and girls aged 12 and older, weighing at least 40 kilos, to treat simple urinary tract infections.UTIs are the most common bacterial infection in women in&nbsp;the UK, with about half of all women in the UK being affected by&nbsp;them. However, patients are at an increasing risk of failure and serious complications, including sepsis and kidney damage, as antibiotic resistance increases.Blujepa acts in a&nbsp;novel way by blocking two bacterial enzymes&nbsp;essential for&nbsp;bacterial replication. It can therefore act on antibiotic-resistant strains such as E. coli.“As the first new type of oral antibiotic to treat uncomplicated UTIs to be approved in nearly three decades, gepotidacin provides a new treatment option for women facing urinary tract infections that can severely impact daily life,” said Julian Beach, Interim Executive Director at the MHRA.&nbsp;The recommended regimen is two tablets twice daily for five days.&nbsp;The approval was based on results from two late-stage Phase 3 studies involving more than 3,100 patients.&nbsp;In those trials, Blujepa was at least as effective as nitrofurantoin, the current standard treatment, even in women with recurrent infections and resistant bacteria, with consistent results.The most common side effects were mild diarrhoea and nausea, affecting more than one in ten patients.On Stocktwits, retail sentiment for GSK was ‘bearish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/GSK">GSK’s stock</a> has risen 22% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Secures UK Approval For First New Oral Antibiotic In 30 Years To Treat Resistant Urinary Tract Infections

The clearance was based on two late-stage Phase 3 trials involving more than 3,100 patients, where Blujepa proved at least as effective as the current standard treatment, even in women with recurrent or drug-resistant infections.

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU

Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.

BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.



GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK Plc - ADR

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with $NBIS stock after its $17.4 billion AI infrastructure deal with $MSFT?

Stocktwits

Microsoft Corp

 stock after its $17.4 billion AI infrastructure deal with 

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSK Glaxosmithkline plc - ADR